• US FDA extends review of Bristol Myers' cancer therapy acquired in Celgene deal

    Bristol now expects the agency to announce its decision by Nov. 16 on the therapy known as liso-cel, which it acquired as part of its $74 billion buyout of …

    Read More
  • 0 0